ClinicalTrials.gov
public full text
Public Domain
Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pilot Study to Validate ex Vivo Expression of Specific Biomarkers of Human Resolutive Macrophages#912052
- Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance#325281
- Biological Signatures, Probiotic Among Those With mTBI and PTSD#905685
- Infliximab to Treat Non-Infectious Scleritis#1030750
- Modeling macrophage-T cell interactions in the breast cancer immune microenvironment: from spatial omics to functional validation.#412249
Record · ID 417549
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive